Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GEMINI: An Open-Label, Single-Arm, Phase II Study of Intraoperative Gemcitabine Intravesical Instillation in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma

NCT04398368 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04398368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04398368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GEMINI: An Open-Label, Single-Arm, Phase II Study of Intraoperative Gemcitabine Intravesical Instillation in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Terminated
Start date
June 5, 2020
Completion date
February 2, 2023
Enrollment
25 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

stage 0a renal pelvis and ureter cancer ajcc v8, stage 0a renal pelvis cancer ajcc v8, stage 0a ureter cancer ajcc v8, stage 0is renal pelvis and ureter cancer ajcc v8, stage 0is renal pelvis cancer ajcc v8, stage 0is ureter cancer ajcc v8, stage i renal pelvis and ureter cancer ajcc v8, stage i renal pelvis cancer ajcc v8, stage i ureter cancer ajcc v8, stage ii renal pelvis and ureter cancer ajcc v8, stage ii renal pelvis cancer ajcc v8, stage ii ureter cancer ajcc v8, stage iii renal pelvis and ureter cancer ajcc v8, stage iii renal pelvis cancer ajcc v8, stage iii ureter cancer ajcc v8, stage iv renal pelvis and ureter cancer ajcc v8, stage iv renal pelvis cancer ajcc v8, stage iv ureter cancer ajcc v8